GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (NAS:HALO) » Definitions » Shiller PE Ratio

Halozyme Therapeutics (Halozyme Therapeutics) Shiller PE Ratio : 75.90 (As of May. 21, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Halozyme Therapeutics Shiller PE Ratio?

As of today (2024-05-21), Halozyme Therapeutics's current share price is $44.78. Halozyme Therapeutics's E10 for the quarter that ended in Mar. 2024 was $0.59. Halozyme Therapeutics's Shiller PE Ratio for today is 75.90.

The historical rank and industry rank for Halozyme Therapeutics's Shiller PE Ratio or its related term are showing as below:

HALO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 65.37   Med: 149   Max: 1610
Current: 75.9

During the past years, Halozyme Therapeutics's highest Shiller PE Ratio was 1610.00. The lowest was 65.37. And the median was 149.00.

HALO's Shiller PE Ratio is ranked worse than
79.33% of 150 companies
in the Biotechnology industry
Industry Median: 34.935 vs HALO: 75.90

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Halozyme Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was $0.600. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.59 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Halozyme Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Halozyme Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halozyme Therapeutics Shiller PE Ratio Chart

Halozyme Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 323.92 75.57

Halozyme Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 166.27 114.76 95.40 75.57 69.29

Competitive Comparison of Halozyme Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Halozyme Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Halozyme Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Shiller PE Ratio falls into.



Halozyme Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Halozyme Therapeutics's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=44.78/0.59
=75.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Halozyme Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.6/131.7762*131.7762
=0.600

Current CPI (Mar. 2024) = 131.7762.

Halozyme Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.130 100.560 -0.170
201409 -0.160 100.428 -0.210
201412 -0.040 99.070 -0.053
201503 -0.120 99.621 -0.159
201506 0.020 100.684 0.026
201509 -0.190 100.392 -0.249
201512 0.030 99.792 0.040
201603 -0.160 100.470 -0.210
201606 -0.210 101.688 -0.272
201609 -0.230 101.861 -0.298
201612 -0.210 101.863 -0.272
201703 -0.260 102.862 -0.333
201706 -0.230 103.349 -0.293
201709 0.020 104.136 0.025
201712 0.850 104.011 1.077
201803 -0.190 105.290 -0.238
201806 -0.160 106.317 -0.198
201809 -0.190 106.507 -0.235
201812 -0.010 105.998 -0.012
201903 0.010 107.251 0.012
201906 -0.100 108.070 -0.122
201909 -0.170 108.329 -0.207
201912 -0.240 108.420 -0.292
202003 -0.040 108.902 -0.048
202006 0.190 108.767 0.230
202009 0.250 109.815 0.300
202012 0.500 109.897 0.600
202103 0.190 111.754 0.224
202106 0.620 114.631 0.713
202109 1.480 115.734 1.685
202112 0.460 117.630 0.515
202203 0.430 121.301 0.467
202206 0.160 125.017 0.169
202209 0.440 125.227 0.463
202212 0.420 125.222 0.442
202303 0.290 127.348 0.300
202306 0.560 128.729 0.573
202309 0.610 129.860 0.619
202312 0.650 129.419 0.662
202403 0.600 131.776 0.600

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Halozyme Therapeutics  (NAS:HALO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Halozyme Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Halozyme Therapeutics (Halozyme Therapeutics) Business Description

Traded in Other Exchanges
Address
12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Executives
Michael J. Labarre officer: SVP, Chief Technical Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Helen Torley director, officer: President and CEO C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
James M Daly director INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Jeffrey William Henderson director 7000 CARDINAL PLACE, DUBLIN OH 43017
Nicole Labrosse officer: SVP, Chief Financial Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Matthew L. Posard director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Akiko Moni Miyashita director 20725 S. WESTERN AVENUE, SUITE 136, TORRANCE CA 90501
Mark Howard Snyder officer: SVP, General Counsel 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Matsui Connie director 3030 CALLAN RD, SAN DIEGO CA 92121
Jean-pierre Bizzari director 235 LAUREL LN, HAVERFOLD PA 19041
Kenneth J Kelley director 1331 HILLVIEW DRIVE, MENLO PARK CA 94025
Elaine D Sun officer: SVP, Chief Financial Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Masaru Matsuda officer: SVP, General Counsel 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Benjamin Hickey officer: SVP, Chief Commerical Officer C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121